National Recognition in Transplant Medicine: GoBroad-affiliated haematology institutions, including Shanghai ZhaXin and LiQuan centres, have been ranked among China’s Top 30 hematopoietic stem cell transplant centres for three consecutive years, reflecting sustained excellence in complex transplant care.
International Professional Acceptance: In 2025, GoBroad haematology programs were formally admitted to the European Society for Blood and Marrow Transplantation (EBMT), underscoring compliance with internationally recognised clinical and research standards.
Prestigious Scientific & Technological Awards: Senior physicians and research teams associated with GoBroad have received multiple high-level national honours for advancements in haematology and oncology, including:
Second Prize, Scientific and Technological Progress Award from the Ministry of Education of China and the Chinese Medical Association for pioneering work in allogeneic HSCT for refractory malignant hematologic diseases.
Chinese Medical Science and Technology Award for contributions to clinical innovation.
Chinese Pharmaceutical Association Science and Technology Innovation Award recognising translational research impact.
Beijing Science and Technology Award for advancements in medical science and patient outcomes.
Chinese Anti-Cancer Association Science and Technology Award for leadership in oncology research.
Leadership in Advanced Therapies: Beijing GoBroad Hospital is widely recognised as a leading centre for CAR-T cell therapy, integrating clinical care with cutting-edge research and innovation.
Ask your healthcare adviser for the best multiple options and choose the one that meets your expectations
Request for an Expert Opinion
Featured Telemedicine Doctors
Explore Top Hospitals for Proton Therapy treatment